Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 3 · 50%High 1 · 16.7%

CHRONIC: Beta‐blockers vs placebo

Heart failure hospitalisation (RR) · heart failure with chronic kidney disease

CHRONIC: Beta‐blockers showed no clear difference in heart failure hospitalisation ( compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
RR 0.67 [0.43, 1.05]
3 studies · 2287 participants
Low

Beta‐blockers vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

It is very uncertain whether beta‐blockers changes heart failure hospitalisation (RR) compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.73 [0.47, 1.13]
4 studies · 449 participants
Very low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.86 [0.64, 1.15]
3 studies · 1019 participants
Moderate

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.92 [0.83, 1.02]
3 studies · 7254 participants
High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.82 [0.69, 0.98]
3 studies · 3714 participants
Moderate

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.89 [0.8, 1]
2 studies · 7362 participants
Moderate